Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $276,000.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $22.08, for a total transaction of $276,000.00. Following the sale, the insider owned 915,188 shares of the company’s stock, valued at approximately $20,207,351.04. The trade was a 1.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Enliven Therapeutics Price Performance

ELVN opened at $20.61 on Friday. The firm has a fifty day moving average price of $20.16 and a 200 day moving average price of $19.68. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.78. The stock has a market cap of $1.22 billion, a P/E ratio of -10.31 and a beta of 0.85.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. Equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

ELVN has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $41.20.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after acquiring an additional 2,630 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $60,000. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after acquiring an additional 2,500 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.